J&J strikes CDMO deal to add capacity for COVID-19 vaccine

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Metamorworks)
(Image: Getty/Metamorworks)

Related tags: Johnson & johnson, COVID-19, Coronavirus, Emergent biosolutions

J&J agrees a manufacturing partnership with Emergent, as it looks to hit its target of one billion doses.

At the end of March​, Johnson & Johnson announced that it had chosen its lead candidate to take forward in clinical trials. At the same time, the company stated it aimed to build capacity to enable the manufacture of one billion doses across its global network.

In pursuing this capacity, J&J has revealed a partnership with Emergent BioSolutions to support the manufacture of its lead COVID-19 vaccine candidate.

As part of the deal, Emergent will provide drug substance manufacturing capabilities through its ‘molecule-to-market’ service.

In addition, the contract development and manufacturing organization (CDMO) will reserve operations capacity should J&J’s vaccine reach the commercial stage, which is anticipated to be possible in 2021.

Emergent stated that the deal would be worth approximately $135m (€124m) and it would produce doses of the vaccine from its Baltimore, US, facility.

The Bayview site was developed through a public-private partnership with the US Department of Health and Human Services, which had been established to prepare and respond to public health emergencies.

Further agreements to come

In its statement, J&J outlined that this deal is the ‘first in a series’ of global collaborations expected to be necessary to expand to the one billion dose-scale.

In terms of the progress of its lead vaccine, J&J noted that it had begun preparing for clinical vaccine production at its facility in Leiden, the Netherlands, and had a potential start date for Phase I studies in September 2020.

The company reaffirmed that the vaccine would be ‘affordable’ and available on a ‘not-for-profit’ basis for emergency pandemic use.

As well as working with partners, the company stated that it is working to scale up its own vaccine manufacturing capabilities globally and had already begun production ‘at risk’, as J&J had previously announced.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us


View more